

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

NCT07193810

Status	RECRUITING
Phase	Early Phase 1
Sponsor	CytoCares Inc
Enrollment	6 participants

Key Eligibility Criteria

Inclusion (26)

- Fully understand the trial's purpose, nature, methodology, and potential adverse reactions, voluntarily participate as a subject, and sign the informed consent form.
- Aged 18-65 years (inclusive, based on the date of signing the informed consent form), regardless of gender.
- For Systemic Lupus Erythematosus (SLE):
- Diagnosed with SLE according to the 2019 EULAR/ACR classification criteria
- Meet at least one of the following: positive antinuclear antibody (ANA) and/or anti-dsDNA antibody and/or anti-Sm antibody at screening

... and 21 more (see full listing online)

Exclusion (24)

- Severe lupus nephritis within 8 weeks prior to screening (defined as urinary protein ≥ 6 g/24 h, serum creatinine ≥ 2.5 mg/dL or 221 $\mu\text{mol/L}$), requirement of prohibited medications for active nephritis per protocol, need for hemodialysis, or receipt of prednisone ≥ 100 mg/day (or equivalent glucocorticoids) for ≥ 14 days.
- Central nervous system disorders (including but not limited to epilepsy, psychosis, interstitial encephalopathy syndrome, cerebrovascular accident, encephalitis, or CNS vasculitis) within 8 weeks prior to screening.
- Other types of idiopathic inflammatory myopathies: inclusion body myositis, amyotrophic diabetes, or juvenile myositis; patients with severe muscle damage or permanent weakness/cardiac involvement due to non-IIM causes (e.g., stroke).
- SSc-related pulmonary hypertension requiring treatment; rapidly progressive SSc-related lower gastrointestinal (small/large intestine) involvement requiring parenteral nutrition; active gastric antral vascular ectasia; history of SSc-related renal crisis.
- History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation.

... and 19 more (see full listing online)

Locations (1 total)

Deyang People's Hospital, Deyang, Sichuan, China

<https://clinicaltrials.gov/study/NCT07193810>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).